Vaxinnate Corp., of Cranbury, N.J., has initiated double-blind, randomized, active comparator-controlled phase II study to evaluate the safety and immunogenicity of its VAX2012Q quadrivalent seasonal influenza vaccine candidate. The active comparator is Sanofi Pasteur Inc.'s Fluzone Quadrivalent.